New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2014
09:17 EDTOREXOrexigen looking for FDA approval in next few months, says Cowen
Cowen noted Orexigen announced Q4 results last night and provided an update on its regulatory processes. The firm remains positive on Contrave's potential lifecycle management opportunities and reiterates its Outperform rating and $10 price target.
News For OREX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 23, 2015
10:02 EDTOREXOn the Fly: Analyst Initiation Summary
Subscribe for More Information
January 22, 2015
16:15 EDTOREXOrexigen initiated with an Outperform at RBC Capital
Subscribe for More Information
January 13, 2015
14:30 EDTOREXOrexigen CEO says 'really pleased' with Contrave launch so far
Narachi says "engaged deeply in conversations" with potential European partners for Contrave weight loss drug. Orexigen CEO Mike Narachi speaking on CNBC.
07:42 EDTOREXJPMorgan to hold a conference
33rd Annual Healthcare Conference is being held in San Francisco on January 12-15 with webcasted company presentations to begin on January 13 at 10:30 am; not all company presentations may be webcasted. Webcast Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use